Pluripotent stem cell-derived pancreatic islet-like cell clusters (SC-islets) are under development as a potential cellular therapy for type 1 diabetes. The capability to generate large numbers of SC-islets in bioreactors could meet transplantation needs for many recipients per production batch. However, translating laboratory-scale differentiation into a clinically useful, large-scale manufacturing process presents bioprocess and translational challenges.
Suspension culture in stirred tank or vertical wheel bioreactors is an established route for scalable SC-islet production but can impose hydrodynamic forces that damage cells and promote aggregate agglomeration during scale-up. The authors hypothesized that microencapsulation in emulsion-generated, high-concentration alginate beads would: prevent cellular agglomeration, reduce mechanical stress during extended suspension culture, and preserve differentiation potential and functional maturation through to transplantation.
Building on prior work where an emulsion-based encapsulation process improved graft survival of murine beta cells, the study presents a full pipeline for microencapsulating human SC-islets. The encapsulation approach uses an emulsion method to generate high-concentration alginate beads designed to house Stage 6 SC-islets for downstream bioreactor culture and final Stage 7 maturation prior to transplantation. The abstract does not provide step-by-step procedural parameters within this summary.
Encapsulated Stage 6 SC-islets were maintained in suspension bioreactor culture for an extended period (25 days) to test whether encapsulation mitigates issues that arise during scale-up, such as cell loss and aggregate coalescence. The pipeline includes continued maturation to Stage 7 within the bioreactor prior to transplantation.
Encapsulation demonstrably prevented cellular agglomeration during the 25-day extended suspension culture. Quantitatively, encapsulated cultures showed improved cell recovery: 91 ± 3% compared with 60 ± 10% for non-encapsulated aggregates. In functional assays, the study reports no significant differences in glucose-stimulated insulin secretion between encapsulated and non-encapsulated SC-islets in vitro, indicating that encapsulation did not impair the capacity for glucose-responsive hormone release in culture.
Stage 7 SC-islets that matured in the bioreactor were transplanted in two formats: encapsulated islets delivered via the intraperitoneal route, and free (non-encapsulated) SC-islets implanted under the kidney capsule. Following transplantation, grafts produced glucose-responsive human C-peptide and remained functional in vivo for up to 98 days, demonstrating maintained endocrine activity after the encapsulation and bioreactor maturation pipeline.
The work establishes a scalable encapsulation platform intended to bridge biomanufacturing scale-up and transplantation readiness for SC-islet therapies. Key proposed advantages include preventing unwanted aggregate agglomeration, reducing mechanical stress encountered during large-scale suspension culture, preserving cell yield through processing, and enabling delivery of functionally mature SC-islets suitable for transplantation. The authors present this as a generalizable strategy that could apply to other encapsulated organoid systems beyond pancreatic islets.
Several authors report relationships with Cellterix Biomedical Inc., including board memberships and equity holdings. Funding sources disclosed include Diabetes Canada; Canadian Institutes of Health Research; Breakthrough Type 1 Diabetes; Natural Sciences and Engineering Research Council of Canada; Canadian Donation and Transplantation Research Network & Cardiometabolic Health, Diabetes and Obesity – CMDO Research Network. Procedural specifics, such as exact emulsion conditions, bead mechanical properties, cell dosing for transplantation, and detailed in vivo metrics beyond duration of functional persistence, were not reported in the abstract and would require consultation of the full text or supplementary materials.
An emulsion-generated, high-concentration alginate encapsulation pipeline can be integrated with extended bioreactor suspension culture to support SC-islet maturation and transplantation readiness. Encapsulation reduced agglomeration and increased cell recovery without detectable loss of glucose-responsive secretion in vitro, and encapsulated grafts produced glucose-responsive human C-peptide and functioned for up to 98 days in vivo. The approach offers a scalable, transplantation-ready platform to support broader translation of SC-islet and potentially other organoid-based therapies.